NeuroCes™ is a medical device that can also be used to treat symptoms of depression, anxiety, and insomnia associated with disorders defined in the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) published by the American Psychiatric Association.
Anxiety Disorders
-
Generalized Anxiety Disorder (GAD): Persistent and uncontrollable worry.
-
Social Anxiety Disorder (Social Phobia): Fear of being judged by others.
-
Panic Disorder: Sudden episodes of intense fear accompanied by physical symptoms.
-
Obsessive-Compulsive Disorder (OCD): Recurrent thoughts and compulsive behaviors.
Depressive Disorders
-
Major Depressive Disorder (MDD): Severe depression that interferes with daily functioning.
-
Persistent Depressive Disorder (Dysthymia): A less severe but long-lasting depressive state.
Sleep Disorders
-
Insomnia: Difficulty falling asleep or staying asleep.
-
Substance/Medication-Induced Sleep Disorder: Sleep disturbances caused by substances or medications.
Bipolar Disorders
-
Bipolar I and II Disorders: Alternating phases of elevated mood (mania/hypomania) and depressive episodes.
-
Cyclothymia: Chronic mood fluctuations that are less severe in intensity.
Neurodevelopmental Disorders
-
Autism Spectrum Disorder (ASD): Difficulties in social communication and repetitive behaviors.
-
Attention-Deficit/Hyperactivity Disorder (ADHD): Problems with attention, impulsivity, and hyperactivity.
150+
Clinical studies and publications
5000+
Active NeuroCes™ users
94%
User satisfaction rate
200+
Therapists & clinics use NeuroCes™
Clinically Approved and CE-Certified Drug-Free Treatment
NeuroCes™ is a portable, battery-operated medical device that is clinically approved and CE-certified.
It is intended for the treatment of anxiety, depression, and insomnia through Cranial Electrotherapy Stimulation (CES), a scientifically validated, safe, and non-invasive neuromodulation method.
NeuroCes™ provides a reliable, drug-free alternative for those seeking an effective treatment.
Drug-Free Treatment and Support with NeuroCes™
01 – Clinically Approved Depression Treatment
DEPRESSION
Depression involves persistent low mood, diminished motivation, and impaired daily functioning. NeuroCes™, via Cranial Electrotherapy Stimulation (CES), modulates mood-related neural pathways, supporting reduction of depressive symptoms and improved emotional regulation.
02 – Clinically Approved Anxiety Treatment
ANXIETY
Anxiety is characterized by excessive worry, tension, and heightened physiological arousal. NeuroCes™, through CES, helps regulate autonomic and cortical activity, supporting decreased anxiety responses, improved stress tolerance, and more stable emotional processing in daily life.
03 – Clinically Approved Insomnia Treatment
INSOMNIA
Insomnia includes difficulty initiating or maintaining sleep, leading to non-restorative rest and daytime fatigue. NeuroCes™, via CES, assists in regulating neural rhythms associated with sleep-wake cycles, supporting deeper, more continuous sleep and improved restorative recovery.
04 – Complementary Treatment Option
BIPOLAR DISORDER
Bipolar disorder involves alternating depressive and elevated mood episodes with significant functional impact. NeuroCes™, through CES, may support modulation of mood-regulating neural circuits, contributing to greater mood stability when integrated within comprehensive clinical care.
Professional and Personal Use
NeuroCes™ has been intended for professional and personal use. NeuroCes™ can be used in hospitals and clinics as well as at home without medical supervision. NeuroCes™ has the advantage of being safely used by individuals at home.
Treatment Effectiveness
Cranial Electrotherapy Stimulation method is a well-researched, safe, effective, and cost-effective to manage mood and sleep disorders. Feedback obtained over time from NeuroCes™ users suffering from these disorders has proven that NeuroCes™ is effective.
Clinical Improvement Rates with CES
DEPRESSION
Clinical Improvement Range: 25%–80%
So far, at least 18 scientific studies have been published on depression, with an average improvement of 47% reported. The improvement found in various studies has ranged from 25% to 80% (Smith, 2007).
ANXIETY
Clinical Improvement Range: 31%–97%
As of now, there have been at least 38 anxiety studies published, with an average 58% improvement. The improvement found in various studies has ranged from 31% to 97%. This is thought to be very important in that anxiety is thought to underlie as much as 90% of illnesses seen by medical practitioners (Smith, 2007).
INSOMNIA
Clinical Improvement Range: 37%–93%
So far we have more than 18 sleep studies in the scientific literature, with treated patients reporting an average of 62% improvement in sleep. The improvement found among the various studies has ranged from 37% to 93% (Smith, 2007).
A New Beginning Without Medication
"I had been looking for a drug-free solution for a long time. By using NeuroCes™ for my anxiety and depression, I noticed not only an improvement in my emotional state but also a clear progress in the quality of my sleep. I sleep more deeply and wake up refreshed. NeuroCes™ has truly given me a new start."
Jean-Pierre, Lyon
Action Mechanism of NeuroCes™
Calming of Overactive Brain Regions
NeuroCes™ deactivates brain regions associated with overuse consistent with various disorders such as depression, anxiety and insomnia.
Restoration of Functional Neural Balance
NeuroCes™ can normalize the balance in functional connectivity of intrinsic neural circuits in the brain.
EEG Wave Balance: Increased Alpha Waves, Decreased Beta and Delta Waves
NeuroCes™ increases alpha activity (inducing relaxation and a pleasant state of well-being), decreases delta (increasing attention and alertness) and beta activity (decreasing compulsive thoughts).
Neurochemical Regulation and Cortisol Reduction
NeuroCes™ increases the concentration of neurochemicals such as serotonin and noradrenaline and decreases cortisol in the brain which results in improved mood and improved sleep.
Quality & Standards
NeuroCes™ Cranial Electrotherapy Stimulator has been approved and CE certified as a therapeutic medical device for both clinical use and personal use in the treatment of Depression, Anxiety and Insomnia.
CE Certification
NeuroCes™ has been certified by the Slovenian Institute of Quality and Metrology (SIQ), a Notified Body, in accordance with Directive 93/42/EEC concerning medical devices (MDD) and the relevant provisions of Regulation (EU) 2017/745 (MDR). The device has been classified as an active Class IIa medical device under Annex IX of the MDD. This classification confirms that its physiological effects are achieved independently of medication, through physical mechanisms such as electromodulation.
EN ISO 13485 Certification
The manufacturer of NeuroCes™, NEUROSANTE, has been granted EN ISO 13485 certification by the Slovenian Institute of Quality and Metrology (SIQ) — an internationally recognized standard for quality management systems applied to medical devices. This certification confirms that production processes comply with international standards, ensuring product safety, traceability, and reliability. It serves as a key reference of quality and trust for NEUROSANTE.
NeuroCes™ in the Treatment of Symptoms Associated with DSM-5 Disorders
Cranial Electrotherapy Stimulation (CES)
The CES device has been proven to inhibit, delay, and reverse the first stages of many neuropsychiatric illnesses. It is also extremely successful in preventing the exacerbation of anxiety, stress, depression, insomnia and rage. Many have found the device helpful in combating problems such as alcohol and drug addiction. It may be the most important breakthrough in electromagnetic field prophylaxis (Smith, 2007).
Clinically Supported Benefits
Following CES treatment, most patients feel less anxious, less distressed, and more focused on mental tasks. Patients with positive outcomes generally sleep better and report improved concentration, increased learning abilities, enhanced recall, and a heightened state of wellbeing after one or a series of CES treatments (Gilula, 2005).
Safety
CES has a foundation of research and clinical use from which proof of safety and effectiveness have been well established. NeuroCes™ is non-invasive and side-effects are mild and self-limiting. Significant side effects or complications attributable to the application of electric current for therapeutic effect are “virtually nonexistent”.
Evidence Beyond Placebo
Components of CES administration, including the level of current, pulse width, electrode placement, frequency, waveform, the number of treatments, and duration of treatment, have all been varied without causing injury or preventing positive therapeutic results. Such efficacy in the face of altering so many variables may suggest a placebo effect is responsible for benefit seen with CES; however, multiple double blind studies and animal research has shown that the placebo effect is not responsible for the benefits documented (Kennerly, 2006). No placebo effect in CES treatment has ever been found when that effect was specifically controlled for (Smith, 2007).
A Modern, Non-Invasive Option
For patients suffering from depression, anxiety, or insomnia who do not achieve sufficient benefit from pharmacotherapy, or who seek alternatives due to side effects, the NeuroCes™ Cranial Electrotherapy Stimulator offers a safe and effective therapeutic option. In addition, NeuroCes™ may help reduce the transient adverse effects often observed at the start of treatment with certain selective serotonin reuptake inhibitors (SSRIs), such as activation, restlessness, or tension. Thus, NeuroCes™ serves both as a drug-free alternative for those seeking a non-pharmacological approach and as a complementary support to existing medication-based treatments.
REFERENCES :
(Smith, 2007). Ray B. Smith, Ph. D. Cranial Electrotherapy Stimulation: It’s First Fifty Years, Plus Three: A Monograph. ISBN: 978-1-60247-589-2 & Cranial Electrotherapy Stimulation Lecture.
(Shealy, 1998). Shealy, C. Norman, Cady, Roger K., Culver-Veehoff, Diane, Cox, Richard & Liss, Saul. Cerebralspinal fluid and plasma neurochemicals: response to cranial electrical stimulation. Journal of Neurological and Orthopaedic Medicine and Surgery. 18(2):94-97, 1998.
(Gilula, 2005). Marshall F. Gilula, MD, Daniel L. Kirsch, PhD. Cranial Electrotherapy Stimulation Review: A Safer Alternative to Psychopharmaceuticals in the Treatment of Depression.
(Kennerly, 2006). Kennerly, Richard C. Changes in quantitative EEG and low resolution tomography following cranial electrotherapy stimulation. August 2006, 425 pp., 81 tables, 233 figures, 171 references.